Drug
Tamoxifen clinical trials
Also written Nolvadex, Soltamox, ICI-46474 and ICI 46,474.
- studies test it
- 215
- open now
- 25
- in phase 3
- 73
- first study started
- 1990
Keep track of what changes. Save the Tamoxifen studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Other names
Studies by the year they started
211 studies that test it; most in 2017 (14)
| Year | Studies |
|---|---|
| 1990 | 2 |
| 1991 | 1 |
| 1992 | 2 |
| 1993 | 6 |
| 1994 | 2 |
| 1995 | 4 |
| 1996 | 6 |
| 1997 | 4 |
| 1998 | 6 |
| 1999 | 2 |
| 2000 | 6 |
| 2001 | 7 |
| 2002 | 8 |
| 2003 | 7 |
| 2004 | 7 |
| 2005 | 4 |
| 2006 | 6 |
| 2007 | 6 |
| 2008 | 8 |
| 2009 | 5 |
| 2010 | 5 |
| 2011 | 7 |
| 2012 | 3 |
| 2013 | 4 |
| 2014 | 7 |
| 2015 | 11 |
| 2016 | 7 |
| 2017 | 14 |
| 2018 | 7 |
| 2019 | 6 |
| 2020 | 4 |
| 2021 | 7 |
| 2022 | 8 |
| 2023 | 5 |
| 2024 | 5 |
| 2025 | 7 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 3
- Phase 1
- 23
- Phase 2
- 102
- Phase 3
- 73
- Phase 4
- 13
- No phase
- 11
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 27 · Other 188
National Cancer Institute (NCI) (8) · AstraZeneca (8) · ETOP IBCSG Partners Foundation (4) · Institut Claudius Regaud (4) · Sun Yat-sen University (4) · University of California, San Francisco (4) · European Institute of Oncology (3) · Austrian Breast & Colorectal Cancer Study Group (3)
Often tested with
Tested in the same studies.
Anastrozole (27) · Exemestane (25) · Letrozole (23) · Fulvestrant (10) · Goserelin (5) · Doxorubicin (5) · Cisplatin (4) · Toremifene (4)
Studies
Open first, then newest update. How each study uses Tamoxifen is read from its arms, and is right about nine times in ten.
Testing it · 215
- Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA StudyEnrolling by invitationPhase 3Tolmar Inc.NCT05645536Written as Tamoxifen
- Clinical Trial to Observe the Effects of Tamoxifen on Testosterone Recovery in Medically Castrated Prostate Cancer PatientsRecruitingPhase 2University Health Network, TorontoNCT07535905Written as Tamoxifen
- Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate ResectionRecruitingPhase 1University of NebraskaNCT06320990Written as Tamoxifen 20mg
- A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06979596Written as Tamoxifen
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceRecruitingPhase 3Stemline Therapeutics, Inc.NCT06492616Written as Tamoxifen
- ETHAN - ET for Male BCRecruitingPhase 2Jose Pablo LeoneNCT05501704Written as Tamoxifen
- Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE TrialRecruitingPhase 2National Cancer Institute (NCI)NCT06184750Written as Tamoxifen
- Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence ScoreRecruitingPhase 2Washington University School of MedicineNCT02476786Written as Tamoxifen
- FES Imaging to Optimize Tamoxifen for Metastatic Breast CancerRecruitingEarly Phase 1University of Wisconsin, MadisonNCT04174352Written as Tamoxifen
- Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors TrialRecruitingPhase 3University of California, San FranciscoNCT03011684Written as Tamoxifen
- Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast CancerRecruitingPhase 2Roswell Park Cancer InstituteNCT06434064Written as Tamoxifen
- Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast CancerNot yet recruitingPhase 2Dana-Farber Cancer InstituteNCT07499999Written as Tamoxifen
- Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After SurgeryRecruitingPhase 2University of ChicagoNCT06348134Written as Tamoxifen
- Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators.Not yet recruitingPhase 2Azienda Ospedaliera Universitaria Integrata VeronaNCT07289035Written as Tamoxifen Citrate 20Mg Tab
- Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.RecruitingPhase 2Andrea DeCensiNCT06364267Written as Tamoxifen 10 MG
- Tamoxifen Versus Etoposide After First Recurrence in GBM PatientsRecruitingPhase 2AHS Cancer Control AlbertaNCT04765098Written as Tamoxifen
- Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast CancerNot yet recruitingPhase 3Region Örebro CountyNCT06223698Written as Tamoxifen
- Tamoxifen for Advanced Solid Pseudopapillary Tumor of the PancreasRecruitingPhase 2Fudan UniversityNCT06914674Written as Tamoxifen 20 mg
- Maintenance Hormonal Therapy and DLBCLNot yet recruitingPhase 2/3Sohag UniversityNCT06355401Written as Tamoxifen 20mg
- A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.RecruitingPhase 2St Vincent's HospitalNCT03906669Written as Tamoxifen and Prometrium
See all 215 studies that test Tamoxifen →
Given in every arm · 65 — Tamoxifen is usual care beside what is tested
- Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsRecruitingPhase 1/2PfizerNCT04557449Written as Tamoxifen
- Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast CancerRecruitingPhase 2University of WashingtonNCT06179303Written as Tamoxifen
- A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)RecruitingPhase 2M.D. Anderson Cancer CenterNCT05035836Written as Tamoxifen
- Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving SurgeryRecruitingPhase 3Fudan UniversityNCT07762885Written as tamoxifen
- Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk ReductionRecruitingPhase 2National Cancer Institute (NCI)NCT06195306Written as Tamoxifen
- Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post ConsolidationRecruitingEarly Phase 1C17 CouncilNCT06942039Written as Tamoxifen
- First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsRecruitingPhase 1/2Eli Lilly and CompanyNCT05768139Written as Tamoxifen
- Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical StudyRecruitingPhase 2Fujian Cancer HospitalNCT07581834Written as Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen
- Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)RecruitingPhase 3Fudan UniversityNCT05891093Written as Tamoxifen
- S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast CancerActive, not recruitingPhase 3SWOG Cancer Research NetworkNCT01674140Written as tamoxifen citrate
- Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast CancerActive, not recruitingPhase 3Tolmar Inc.NCT04906395Written as Tamoxifen
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast CancerActive, not recruitingPhase 3National Cancer Institute (NCI)NCT01272037Written as Tamoxifen Citrate
- Roll-over Study to Allow Continued Access to RibociclibActive, not recruitingPhase 4Novartis PharmaceuticalsNCT05161195Written as Tamoxifen
- Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)Active, not recruitingPhase 3National Cancer Institute (NCI)NCT00310180Written as Tamoxifen Citrate
- A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone TherapyActive, not recruitingPhase 3Astellas Pharma Global Development, Inc.NCT06440967Written as Tamoxifen
- Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam TrialSuspendedPhase 3Alliance for Clinical Trials in OncologyNCT06671912Written as Tamoxifen
- Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast CancerCompletedPhase 3National Cancer Institute (NCI)NCT00601900Written as Tamoxifen Citrate
- TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast CancerActive, not recruitingPhase 2Dana-Farber Cancer InstituteNCT06001762Written as Tamoxifen
- Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)Active, not recruitingPhase 2Dana-Farber Cancer InstituteNCT02764541Written as Tamoxifen
- Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast CancerCompletedPhase 2City of Hope Medical CenterNCT00003042Written as tamoxifen citrate
Showing 20 of 65.
As the comparator · 47 — what is tested is compared with Tamoxifen
- A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyRecruitingPhase 3AstraZenecaNCT05774951Written as Tamoxifen
- A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast CancerRecruitingPhase 2Eli Lilly and CompanyNCT07287098Written as Tamoxifen 20 mg
- Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)RecruitingPhase 3European Organisation for Research and Treatment of Cancer - EORTCNCT05512364Written as Tamoxifen
- DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as TreatmentRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT06075953Written as Tamoxifen
- Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast CancerRecruitingPhase 2National Cancer Institute (NCI)NCT05941520Written as Tamoxifen
- Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After LumpectomyRecruitingPhase 2UNC Lineberger Comprehensive Cancer CenterNCT05472792Written as tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene
- A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast CancerRecruitingPhase 3Shandong Suncadia Medicine Co., Ltd.NCT07349069Written as Tamoxifen Citrate Tablets
- Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast CancerRecruitingPhase 2SOLTI Breast Cancer Research GroupNCT05982093Written as Tamoxifen 20 mg
- Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)RecruitingPhase 3Japanese Foundation for Cancer ResearchNCT07190443Written as Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen
- A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast CancerRecruitingPhase 2Royal Marsden NHS Foundation TrustNCT04985266Written as Tamoxifen
- Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young WomenRecruitingPhase 3First Affiliated Hospital, Sun Yat-Sen UniversityNCT02914158Written as Tamoxifen
- An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)Active, not recruitingPhase 3AstraZenecaNCT05952557Written as Tamoxifen
- Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity CancerCompletedPhase 2/3National Cancer Institute (NCI)NCT02101788Written as Tamoxifen Citrate
- A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)Active, not recruitingPhase 3Genentech, Inc.NCT05306340Written as Tamoxifen
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerActive, not recruitingPhase 3Eli Lilly and CompanyNCT05514054Written as Tamoxifen
- Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%CompletedPhase 2MedSIRNCT05659563Written as Tamoxifen
- Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast CancerTerminatedPhase 2SanofiNCT04059484Written as Tamoxifen
- Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast CancerCompletedPhase 3ETOP IBCSG Partners FoundationNCT00066703Written as tamoxifen
- Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related ToxicityTerminatedPhase 3SanofiNCT05128773Written as Tamoxifen
- ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast CancerActive, not recruitingPhase 3Azienda Ospedaliero-Universitaria CareggiNCT04134598Written as Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen
Showing 20 of 47.
Codes
What other systems call Tamoxifen · ClinicalTrials.gg INT008271
- MeSH (NLM) D013629TamoxifenConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 094ZI81Y45TAMOXIFENConfirmed FDA, NLM, Wikidata
- RxNorm 10324Confirmed FDA, Wikidata
- Wikidata Q412178tamoxifenConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C62078TamoxifenOne source FDA
- DrugBank DB00675One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D013629 | Tamoxifen | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 094ZI81Y45 | TAMOXIFEN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 10324 | — | Confirmed FDA, Wikidata |
| Wikidata | Q412178 | tamoxifen | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C62078 | Tamoxifen | One source FDA |
| DrugBank | DB00675 | — | One source Wikidata |
Also registered as tamoxifen citrate (UNII 7FRV7310N6 · RxNorm 40137).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.